Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,464,201 papers from all fields of science
Search
Sign In
Create Free Account
AZD 2281
Known as:
AZD-2281
, AZD2281
, KU-0059436
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
olaparib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Mechanisms of IKBKE Activation in Cancer
S. Challa
2017
Corpus ID: 90863753
2015
2015
Effects of PARP-1 inhibitors AG-014699 and AZD2281 on proliferation and apoptosis of human hepatoma cell line HepG2
Du Senrong
2015
Corpus ID: 89967045
2015
2015
Der Einfluss des PARP Inhibitors AZD2281 (Olaparib) auf das Wachstum von Mantelzelllymphomen in Abhängigkeit vom ATM und p53 Mutationsstatus
T. Steinbichler
2015
Corpus ID: 103596919
Der PARP Inhibitor AZD2281 ist ein neues Medikament zur gezielten Tumortherapie und ist bei Tumoren mit Defekten in der DNA…
Expand
2014
2014
Abstract 825: The development of a novel PARP inhibitor with potent antitumor activity in various tumor xenograft models
Ji‐Seon Park
,
J. Kim
,
+7 authors
Jeongmi Kim
2014
Corpus ID: 71014559
Poly (ADP-ribose) Polymerase (PARP) plays a critical role in DNA repair processes. Small molecule inhibitors of PARP for the…
Expand
Review
2013
Review
2013
Abstract 1188: BRCA 1/2 mutation status is correlated with increased hypersensitivity reactions to carboplatin.
D. H. Moon
,
J. Hays
,
+5 authors
Jung-Min Lee
2013
Corpus ID: 75256178
Background: Carboplatin (Cp) has become the standard first-line chemotherapeutic agent for treatment of ovarian cancer (OvCa…
Expand
2011
2011
Abstract 2657: Radiosensitization of pancreatic cancer cells by combined inhibition of Chk1 and PARP1 using AZD7762 and olaparib
S. Vance
,
Jonathan Maybuam
,
T. Lawrence
,
M. Morgan
2011
Corpus ID: 71282781
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Small molecule inhibitors targeted to key DNA damage…
Expand
2010
2010
Mismatch repair proficiency as a predictor of response to the PARP inhibitor AZD2281.
R. Redman
,
S. J. York
2010
Corpus ID: 74018157
e13644 Background: Microsatellite instability (MSI), the result of defective DNA mismatch repair (MMR), is observed in…
Expand
2010
2010
The use of poly(ADP-ribose) polymerase (PARP1) inhibitors (AG14361, AZD2281, ABT888) in combination with capecitabine, 5-fluorouracil, or paclitaxel in the treatment of hereditary and sporadic breast…
J. D. Soto
,
R. Quick-Fountain
,
T. Velikodvorskaya
,
N. Fatima
2010
Corpus ID: 73968031
e13120 Background: Poly(ADP-ribose) polymerase (PARP-1) inhibitors have been reported to enhance the cytotoxicity of alkylating…
Expand
2009
2009
Abstract #5494: Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer
C. Knights
,
Lucy C. Riches
,
+10 authors
M. O’Connor
2009
Corpus ID: 82468010
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO The oral PARP inhibitor olaparib (AZD2281, KU-0059436) has been shown to have…
Expand
2009
2009
Alnylam casts IP into pool
Catherine Shaffer
Nature Biotechnology
2009
Corpus ID: 27283225
785 define the role of these drugs in patients with breast cancer and to some extent with ovarian cancer,” says Eric P. Winer…
Expand